FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897543603> ?p ?o ?g. }

• W2897543603 abstract "After several false starts, the era of amyloid-beta positron emission tomography (PET) imaging began in earnest with the presentation of the first Pittsburgh Compound-B (PiB) data at the 2002 International Conference on Alzheimer's Disease in Stockholm. Review of the literature with personal reflections. The use of PiB spread rapidly to PET facilities capable of producing carbon-11, and efforts were already underway to develop fluorine-18-labeled amyloid tracers that would enable greater access to PET scanners without cyclotron facilities and enable widespread clinical use. Early findings documented a frequent presence of amyloid deposition in cognitively normal elderly – a finding that would later have implications on the clinical indications for amyloid imaging. It also became clear that a sizeable fraction of subjects with mild cognitive impairment (MCI) were amyloid-negative – a finding that would help mold subsequent appropriate use criteria. Amyloid tracers were first being employed in clinical trials of anti-amyloid therapies at about the same time that the FDA considered the path to approval for amyloid tracers in clinical use. After ground-breaking trials in terminally ill volunteers, three F-18 tracers were approved for clinical use with an indication to rule out Alzheimer's disease in the absence of amyloid. This was followed by a hearing by the Center for Medicaid and Medicare Services to consider the approval of payment for amyloid imaging scans for Medicare beneficiaries. Possibly related to the absence of a disease modifying anti-amyloid drug, approval was denied, but an option was included for coverage with evidence development – leading to the ongoing study “Imaging Dementia - Evidence for Amyloid Scanning” (IDEAS). Now, in 2018, amyloid imaging: 1) remains a critical element of many studies of aging and Alzheimer's disease; 2) is a basic component for both inclusion in clinical trials and is a primary or secondary outcome of anti-amyloid therapeutic trials; and 3) forms the foundation of new guidelines/frameworks on the clinical and research diagnosis/definition of preclinical, prodromal and probable Alzheimer's disease. However, lack of reimbursement has prevented the widespread clinical use of this technology that was met with so much excitement 15 years before." @default.
• W2897543603 created "2018-10-26" @default.
• W2897543603 creator A5036841670 @default.
• W2897543603 date "2018-07-01" @default.
• W2897543603 modified "2023-10-16" @default.
• W2897543603 title "FTS3‐01‐01: HISTORY OF AMYLOID PET" @default.
• W2897543603 doi "https://doi.org/10.1016/j.jalz.2018.06.2756" @default.
• W2897543603 hasPublicationYear "2018" @default.
• W2897543603 type Work @default.
• W2897543603 sameAs 2897543603 @default.
• W2897543603 citedByCount "0" @default.
• W2897543603 crossrefType "journal-article" @default.
• W2897543603 hasAuthorship W2897543603A5036841670 @default.
• W2897543603 hasConcept C142724271 @default.
• W2897543603 hasConcept C160735492 @default.
• W2897543603 hasConcept C162324750 @default.
• W2897543603 hasConcept C2775842073 @default.
• W2897543603 hasConcept C2776534028 @default.
• W2897543603 hasConcept C2777633098 @default.
• W2897543603 hasConcept C2779134260 @default.
• W2897543603 hasConcept C2781073650 @default.
• W2897543603 hasConcept C2989005 @default.
• W2897543603 hasConcept C502032728 @default.
• W2897543603 hasConcept C50522688 @default.
• W2897543603 hasConcept C535046627 @default.
• W2897543603 hasConcept C71924100 @default.
• W2897543603 hasConceptScore W2897543603C142724271 @default.
• W2897543603 hasConceptScore W2897543603C160735492 @default.
• W2897543603 hasConceptScore W2897543603C162324750 @default.
• W2897543603 hasConceptScore W2897543603C2775842073 @default.
• W2897543603 hasConceptScore W2897543603C2776534028 @default.
• W2897543603 hasConceptScore W2897543603C2777633098 @default.
• W2897543603 hasConceptScore W2897543603C2779134260 @default.
• W2897543603 hasConceptScore W2897543603C2781073650 @default.
• W2897543603 hasConceptScore W2897543603C2989005 @default.
• W2897543603 hasConceptScore W2897543603C502032728 @default.
• W2897543603 hasConceptScore W2897543603C50522688 @default.
• W2897543603 hasConceptScore W2897543603C535046627 @default.
• W2897543603 hasConceptScore W2897543603C71924100 @default.
• W2897543603 hasIssue "7S_Part_18" @default.
• W2897543603 hasLocation W28975436031 @default.
• W2897543603 hasOpenAccess W2897543603 @default.
• W2897543603 hasPrimaryLocation W28975436031 @default.
• W2897543603 hasRelatedWork W1989476860 @default.
• W2897543603 hasRelatedWork W1996778502 @default.
• W2897543603 hasRelatedWork W2000064323 @default.
• W2897543603 hasRelatedWork W2000675125 @default.
• W2897543603 hasRelatedWork W2024398157 @default.
• W2897543603 hasRelatedWork W2165947974 @default.
• W2897543603 hasRelatedWork W2186251212 @default.
• W2897543603 hasRelatedWork W2318587403 @default.
• W2897543603 hasRelatedWork W3034354100 @default.
• W2897543603 hasRelatedWork W86708269 @default.
• W2897543603 hasVolume "14" @default.
• W2897543603 isParatext "false" @default.
• W2897543603 isRetracted "false" @default.
• W2897543603 magId "2897543603" @default.
• W2897543603 workType "article" @default.